Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer
The trial, sponsored by Cancer Trials Ireland, aimed to identify biomarkers predictive of response to docetaxel in patients with hormone-refractory prostate cancer. With an enrollment of 73 patients, the study's completion may provide valuable insights into the utility of mRNA as a predictive biomarker, potentially enhancing treatment personalization in this patient population. The findings could position docetaxel as a more targeted therapy, thereby improving patient outcomes and offering a competitive edge in the prostate cancer treatment market. Given the increasing focus on precision medicine, the results may attract interest from pharmaceutical companies looking to develop companion diagnostics or enhance existing therapies. The commercial implications extend to potential collaborations or licensing opportunities for biomarker development.
Indication: Metastatic Cancer
Modality: small molecule
Target: mRNA in circulating tumor cells as a biomarker for response to docetaxel in hormone-refractory prostate cancer
Sponsor: Cancer Trials Ireland
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: mRNA in circulating tumor cells as a biomarker for response to docetaxel in hormone-refractory prostate cancer
View original source fields
Condition raw: Metastatic Cancer, Prostate Cancer
Condition normalized: Metastatic Cancer, Prostate Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: mRNA in circulating tumor cells as a biomarker for response to docetaxel in hormone-refractory prostate cancer
Target normalized: mRNA in circulating tumor cells as a biomarker for response to docetaxel in hormone-refractory prostate cancer